TCIM
VNDA icon

TIAA CREF Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

TIAA CREF Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$7.07M Sell
384,160
-163,397
-30% -$3.72M 0.01% 1237
2018
Q4 		$14.3M Sell
547,557
-179,466
-25% -$4.22M 0.01% 790
2018
Q3 		$16.7M Buy
727,023
+41,687
+6% +$851K 0.01% 818
2018
Q2 		$13.1M Buy
685,336
+169,254
+33% +$2.83M 0.01% 985
2018
Q1 		$8.7M Buy
516,082
+69,600
+16% +$1.16M 0.01% 1200
2017
Q4 		$6.79M Buy
446,482
+21,595
+5% +$320K ﹤0.01% 1411
2017
Q3 		$7.61M Buy
424,887
+115,205
+37% +$1.93M 0.01% 1326
2017
Q2 		$5.05M Sell
309,682
-99,270
-24% -$1.43M ﹤0.01% 1597
2017
Q1 		$5.72M Buy
408,952
+19,674
+5% +$280K ﹤0.01% 1508
2016
Q4 		$6.21M Buy
389,278
+10,314
+3% +$166K ﹤0.01% 1463
2016
Q3 		$6.31K Buy
378,964
+80,191
+27% +$1.08M ﹤0.01% 1442
2016
Q2 		$3.34M Buy
298,773
+87,527
+41% +$848K ﹤0.01% 1814
2016
Q1 		$1.77M Buy
211,246
+76,700
+57% +$630K ﹤0.01% 2148
2015
Q4 		$1.25M Hold
134,546
– – ﹤0.01% 2452
2015
Q3 		$1.52M Buy
134,546
+5,431
+4% +$66.4K ﹤0.01% 2312
2015
Q2 		$1.64M Buy
129,115
+866
+0.7% +$9.34K ﹤0.01% 2422
2015
Q1 		$1.19M Sell
128,249
-375,446
-75% -$4.24M ﹤0.01% 2520
2014
Q4 		$7.21M Sell
503,695
-3,807
-0.8% -$45K 0.01% 1363
2014
Q3 		$5.27M Sell
507,502
-27,801
-5% -$364K ﹤0.01% 1573
2014
Q2 		$8.66M Buy
535,303
+102,025
+24% +$1.36M 0.01% 1265
2014
Q1 		$7.04M Sell
433,278
-16,116
-4% -$229K 0.01% 1365
2013
Q4 		$5.58M Sell
449,394
-39,396
-8% -$396K ﹤0.01% 1562
2013
Q3 		$5.36M Buy
488,790
+8,361
+2% +$89.3K ﹤0.01% 1537
2013
Q2 		$3.88M Buy
+480,429
New +$3.24M ﹤0.01% 1706

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TIAA CREF Investment Management's VNDA Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Vanda Pharmaceuticals (VNDA) stake by 30% in Q1 2019, selling an estimated $3.72M and leaving 384,160 shares worth $7.07M. The position accounts for 0.01% of the portfolio, ranked #1237.

TIAA CREF Investment Management first reported a position in VNDA in Q2 2013 and has held it in 24 quarters since. The position peaked at $16.7M in Q3 2018. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

  • TIAA CREF Investment Management held 384,160 shares of Vanda Pharmaceuticals worth $7.07M as of Q1 2019.
  • TIAA CREF Investment Management sold 163,397 Vanda Pharmaceuticals shares in Q1 2019, an estimated $3.72M.
  • Vanda Pharmaceuticals made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1237 holding.
  • TIAA CREF Investment Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Vanda Pharmaceuticals position peaked at $16.7M in Q3 2018.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.